title: [Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].
abstract: Imatinib, an antineoplastic drug used to treat certain cancers, has many side effects such as hematologic, neurologic or cutaneous toxicity. These toxicities seem to be due to a high imatinib plasmatic concentration and are frequently controlled by a discontinuation or a dosage reduction of the drug. We report here in 2 cases of cutaneous side effects induced by imatinib in order to demonstrate the necessity of drug monitoring in such cases. In our cases, imatinib is responsible in the occurrence of these side effects. Monitoring plasma levels of imatinib allowed us to judge if levels were toxic or not and to avoid discontinuation of imatinib in some cases.
authors.affiliation: Service de pharmacologie clinique, Centre national de pharmacovigilance, Tunis, Tunisia.
authors.forename: Sameh
authors.initials: S
authors.lastname: Trabelsi
authors.forename: Emna
authors.initials: E
authors.lastname: Gaïes
authors.forename: Samia
authors.initials: S
authors.lastname: Sraïri
authors.forename: Rim
authors.initials: R
authors.lastname: Sahnoun
authors.forename: Riadh
authors.initials: R
authors.lastname: Daghfous
authors.forename: Mohamed
authors.initials: M
authors.lastname: Lakhal
authors.forename: Sihem
authors.initials: S
authors.lastname: El Aïdli
authors.forename: Anis
authors.initials: A
authors.lastname: Klouz
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000097:blood; D001549:Benzamides / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use; D003875:Drug Eruptions / Q000097:blood / Q000150:complications / Q000209:etiology / Q000628:therapy*; D005076:Exanthema / Q000097:blood / Q000139:chemically induced* / Q000150:complications / Q000628:therapy*; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use; D011537:Pruritus / Q000139:chemically induced / Q000150:complications / Q000628:therapy; D011743:Pyrimidines / Q000009:adverse effects* / Q000097:blood* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate
keywords: cutaneous side effect; imatinib